BALVERSA^®: it’s time to take a different direction in 2L+ therapy with the first and only approved oral targeted FGFR3 inhibitor for LA/mUC¹

BALVERSA^® no se encuentra comercializado en España.

BALVERSA^® is a monotherapy indicated for the treatment of adult patients with unresectable LA/mUC harbouring susceptible FGFR3 alterations and who have progressed during or following at least one line
of therapy containing a PD-1 or PD-(L)1 inhibitor in this disease setting.¹

▼ BALVERSA^® is subject to additional monitoring. This will allow for quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at
https://www.janssenmedicalcloud.com/en-us/report-an-adverse-event.

2L+: second-line; FGFR3: fibroblast growth factor receptor 3; LA: locally advanced; mUC: metastatic urothelial carcinoma; PD-1: programmed cell death protein 1; PD-(L)1: programmed cell death ligand 1; SmPC: summary of product characteristics.